Human reproduction最新文献

{"title":"The International Glossary on Infertility and Fertility Care, 2025†.","authors":"Fernando Zegers-Hochschild, Silke Dyer, G David Adamson, Valerie Baker, Kurt Barnhart, Siladitya Bhattacharya, Clare Boothroyd, Georgina Chambers, Jacques De Mouzon, Eman Elgindy, Bart Fauser, Karin Hammarberg, Marcos Horton, Osamu Ishihara, Seung Chik Jwa, Mohamed Khrouf, Markus Kupka, Dolores J Lamb, Martha Luna, A Gustavo Martinez, Brent Monseur, Peter Nagy, Anja Pinborg, Catherine Racowsky, Laura Rienzi, Peter Schlegel, Lone Schmidt, Lan Ngoc Vuong, Tari Turner, Mónica Hebe Vázquez-Levin, Ibrahim Wada, Dagan Wells, Christine Wyns","doi":"10.1093/humrep/deag029","DOIUrl":"https://doi.org/10.1093/humrep/deag029","url":null,"abstract":"<p><strong>Study question: </strong>What updates of the International Glossary on Infertility and Fertility Care are required, to reflect contemporary scientific knowledge, social needs, and inclusive definitions, while harmonizing international communication across clinical, research, policy, and public domains?</p><p><strong>Summary answer: </strong>This 4th edition presents 348 consensus-based terms and definitions, including numerous revisions from the previous edition and 79 newly introduced definitions reflecting advances in reproductive science, technology, and evolving social contexts.</p><p><strong>What is known already: </strong>Previous glossary editions (2006, 2009, 2017) established internationally recognized definitions related to clinical practice, research, and policy. The 2017 edition comprised 283 terms and, among many others, expanded the concept of infertility to include not only its recognition as a disease, but also as an impairment of function generating disability. The glossary has been extensively used worldwide and has contributed to international standardization of data collection, appropriate comparison of outcome measures, and provided a reference for all stakeholders including policy makers.</p><p><strong>Study design, size, duration: </strong>Under guidance of the organizing committee, 21 professionals from across the world, and representing expertise in different sub-specialties, formed five working groups: clinical definitions; outcome measures; embryology laboratory; clinical and laboratory andrology; and epidemiology, public health and gender related definitions. The definitions from the previous glossary were evaluated and new terms identified. All definitions were then reviewed by an international advisory panel of nine experts that evaluated the glossary from scientific, ethical, cultural, and policy perspectives.</p><p><strong>Participants/materials, setting, methods: </strong>Between November 2024 and October 2025, periodical virtual meetings were held within and between working groups and the organizing committee. Following circulation of the first consensually agreed draft, a one-day in-person meeting with representatives of all working groups and members of the international advisory panel was held at ESHRE, June 2025. Most terms and definitions were discussed and agreed. In the absence of agreement, further discussions were held between the organizing committee, working group chairs and members of the advisory panel. It had been determined at the outset that final disagreement would be resolved via a two-third majority vote. All terms and definitions were, however, reached by consensus and adopted following a final round of review and approval by all authors.</p><p><strong>Main results and the role of chance: </strong>The glossary now includes 348 terms. Compared to the previous edition, 14 terms were deleted, numerous terms modified and 79 new terms were added. Modifications reflect current scientific ","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of endometrial preparation on pregnancy loss in vitrified-warmed euploid blastocyst transfer cycles: a randomized controlled trial.","authors":"C Roelens, S Santos-Ribeiro, S Mackens, A De Vos, K Keymolen, P Verdyck, M De Vos, H Tournaye, W Verpoest, C Blockeel","doi":"10.1093/humrep/deag060","DOIUrl":"https://doi.org/10.1093/humrep/deag060","url":null,"abstract":"<p><strong>Study question: </strong>Does artificial cycle (AC) endometrial preparation result in increased pregnancy loss rates in patients undergoing vitrified-warmed euploid blastocyst transfer (frozen embryo transfer (FET))?</p><p><strong>Summary answer: </strong>The randomized controlled trial (RCT) demonstrates that artificial endometrial preparation is associated with significantly higher early pregnancy loss (EPL) compared to natural cycles when transferring euploid embryos.</p><p><strong>What is known already: </strong>The increased use of FET cycles has fueled discussion regarding the optimal endometrial preparation method. While earlier reviews found no significant differences in pregnancy outcomes between preparation strategies, recent studies suggest that artificial preparation may be associated with higher pregnancy loss rates and, more recently, with hypertensive disorders of pregnancy. However, these findings were not confirmed in a recent RCT using genetically untested embryos. Since up to 70% of EPLs are attributed to genetic anomalies in the embryo, analyzing FET of euploid embryos provides a more accurate evaluation of the impact of endometrial preparation on pregnancy loss.</p><p><strong>Study design, size, duration: </strong>An RCT was conducted in a university hospital (May 2019-May 2024) investigating the impact of endometrial preparation on pregnancy loss in FET. A power calculation based on internal data determined that 261 patients per arm were needed to detect an increase in pregnancy loss from 9.9% in tNC-FET to 18.4% in AC-FET (80% power, 5% significance). Due to safety concerns regarding hypertensive disorders following AC-FET, the trial was discontinued after enrolling 354 patients.</p><p><strong>Participants/materials, setting, methods: </strong>Women aged 18-42 years undergoing FET after preimplantation genetic testing for aneuploidy (PGT-A) with or without testing for a monogenic disorder (PGT-M) or a structural chromosomal rearrangement (PGT-SR) were randomized (1:1) to either true NC-FET (spontaneous ovulation without luteal phase support (LPS)) or AC-FET (using estradiol and single-route LPS). Only the first FET per patient using a euploid blastocyst was included. The primary outcome was EPL (before 8 weeks of gestation). Secondary outcomes included clinical pregnancy rate (CPR), ongoing pregnancy, live birth rate (LBR), and obstetric outcomes.</p><p><strong>Main results and the role of chance: </strong>Between May 2019 and May 2024, 354 patients were randomized (NC-FET: 178, AC-FET: 176). In the intention-to-treat analysis, EPL per started FET cycle occurred in 6.7% of patients in the NC-FET group and 14.2% in the AC-FET group (P = 0.022). Additionally, EPL per positive hCG was 9.0% in the NC-FET group and 21.6% in the AC-FET group (P = 0.006). CPRs were significantly higher in the NC-FET group (72.5% versus 52.3%, P < 0.001), as were LBRs (67.4% versus 47.2%, P < 0.001). The study was prematurely terminated ","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147836683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AMH regulates ovary size by counteracting the positive influence of clustered ovarian follicle growth.","authors":"Carmen Lim, Lynn Yiew, Nicholas J Anderson, Peter Smith, Laurel Quirke, Alan Carne, Urooza Sarma, Ryan Rose, Martha Nicholson, Christine L Jasoni, Ping Liu, Simone Petrich, Jenny Juengel, Michael W Pankhurst","doi":"10.1093/humrep/deag022","DOIUrl":"10.1093/humrep/deag022","url":null,"abstract":"<p><strong>Study question: </strong>Does anti-Müllerian hormone (AMH) influence preantral follicle development within a short range of AMH-secreting antral follicles?</p><p><strong>Summary answer: </strong>Immunization of sheep against AMH leads to increased follicle survival, specifically in regions close to small-medium antral follicles.</p><p><strong>What is known already: </strong>Serum AMH is known to inhibit the survival of immature ovarian follicles, but its biological role remains poorly understood. Mammalian ovaries contain many more developing ovarian follicles than are needed for ovulation, but how these systems operate remains unclear.</p><p><strong>Study design, size, duration: </strong>Cross-sectional-control versus treatment studies examining the effects in the presence or absence of AMH.</p><p><strong>Participants/materials, setting, methods: </strong>Anti-AMH immunization experiments were conducted in sheep followed by histological 2D and 3D tissue analysis. Microdialysis was conducted on ex vivo human and sheep ovaries. Live-imaging of a fluorogenic enzyme-responsive reagent was conducted on ex vivo mouse ovaries. Organ/follicle culture was conducted on Amh+/+ and Amh-/- ovary tissues to measure follicle activation and growth rates.</p><p><strong>Main results and the role of chance: </strong>The likely site of action of AMH was shown to be ovarian stroma adjacent to large follicles as microdialysis determined that receptor-activating concentrations of AMH were only observed within a short range of the follicle. The AMH-activating enzymes were also shown to be primarily located in stroma using live-imaging of a fluorogenic enzyme-responsive reagent. Sheep were immunized against AMH protein to inhibit extracellular signalling and the ovaries were examined using 3-dimensional reconstructions of ovarian follicle positions. This showed that inhibition of AMH signalling caused an increase in preantral follicle survival, but almost entirely in proximity to large developing follicles.</p><p><strong>Large scale data: </strong>None.</p><p><strong>Limitations, reasons for caution: </strong>Limited studies were conducted on human tissue but the results concur with the sheep experiments. Sheep ovaries provide a useful large-animal model for comparative anatomy with humans but there will be interspecies differences.</p><p><strong>Wider implications of the findings: </strong>These results add to the evidence that small growing follicle survival is influenced by the proximity of large follicles. This has relevance for conditions where large follicles are lacking (e.g. primary ovary insufficiency) or where follicle growth is excessive (e.g. PCOS).</p><p><strong>Study funding/competing interest(s): </strong>This research was funded by a Sir Charles Hercus Research Fellowship from the Health Research Council of New Zealand (grant number 18-027). The authors have no conflicts of interest to declare.</p><p><strong>Trial registration number: </strong","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":"795-808"},"PeriodicalIF":6.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147305230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The problem with the 'truth': rethinking ground truth for artificial intelligence in endometriosis diagnosis.","authors":"Alison Deslandes, Yuan Zhang, Mathew Leonardi, Hsiang-Ting Chen, Gustavo Carneiro, Jodie Avery, George Condous, Steven Knox, M Louise Hull","doi":"10.1093/humrep/deag024","DOIUrl":"10.1093/humrep/deag024","url":null,"abstract":"<p><p>Artificial intelligence (AI) is revolutionizing how we practice medicine. In areas where we have traditionally struggled, such as diagnosing endometriosis, AI has significant potential to improve the breadth and accuracy of diagnostic services offering a great benefit to patient care. When developing AI models for diagnosis, the 'ground truth' refers to the reference standard used in the labelling of the data used to train the model. Conventionally, in clinical medicine, we correlate any new diagnostic tool to the established 'gold standard', which in the case of endometriosis is laparoscopic visualization of lesions and histological confirmation. This method however is increasingly recognized as imperfect. Acknowledgement of the limitations of surgery and recent improvements in the diagnostic capability of imaging technologies to detect endometriosis, has created a situation where endometriosis no longer has one clear 'gold standard' for diagnosis. In this commentary, we will explore the impact of this on AI-driven endometriosis diagnostic tools and propose novel ways this could be addressed in the context of creating ground truths for endometriosis diagnosis.</p>","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":"650-657"},"PeriodicalIF":6.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13139653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147289864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-cell proteomics reveals cytoplasmic defects in Patl2-deficient oocytes rescued by spindle transfer.","authors":"A Cardona Barberán, E Araftpoor, A Christodoulaki, M Fakhar-I-Adil, J Goethals, A Rybouchkin, C Arnoult, A Boel, M Bühler, K C Pavani, D Stoop, K Gevaert, F Vanden Meerschaut, B Heindryckx","doi":"10.1093/humrep/deag073","DOIUrl":"https://doi.org/10.1093/humrep/deag073","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Study question: &lt;/strong&gt;Can single-cell, mass spectrometry-based proteomics identify proteins associated with reduced developmental competence of Patl2-/- Metaphase II (MII) mouse oocytes and reveal therapeutic targets for Patl2-related infertility?&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Summary answer: &lt;/strong&gt;Abnormal protein content is detected in Patl2-/- MII oocytes, which can be rescued by spindle transfer (ST).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;What is known already: &lt;/strong&gt;PATL2 is an RNA-binding protein that represses maternal mRNA translation during oocyte maturation. PATL2 mutations in humans often cause germinal vesicle (GV) arrest, although some affected patients produce MII oocytes with reduced fertilization and embryo developmental potential. Consequently, oocyte donation is required. The Patl2-/- knockout mouse model offers a unique opportunity to study Patl2-related infertility and evaluate potential treatments.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Study design, size, duration: &lt;/strong&gt;Patl2 -/- mice (C57BL/6NTac-Patl2tm1a), with deletion of exon 7, were bred from April 2021 to October 2023, yielding 36 homozygous females from 271 pups. To investigate the role of Patl2 at the MII stage, in vivo MII oocytes from Patl2-/- and Patl2+/+ females were collected for analysis of key quality markers and single-cell proteomics. Based on these results, maternal ST was tested to rescue abnormal embryo development. At least three replicates were conducted per experiment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Participants/materials, settings, methods: &lt;/strong&gt;Four- to 12-week-old mice underwent superovulation and oocyte collection to assess in vitro and in vivo maturation. In vivo-matured MII oocytes were used to evaluate activation (AR) and blastocyst rates (BR) after PIEZO-ICSI, spindle configuration, and calcium oscillatory patterns following SrCl2 exposure. Vitrified-warmed oocytes were used for single-cell proteomics using a timsTOF ultra mass spectrometer operated in diaPASEF mode. ST involved transferring the Patl2-/- spindle to Patl2+/+ enucleated cytoplasm, followed by parthenogenetic activation (PA) via SrCl2 exposure.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main results and the role of chance: &lt;/strong&gt;Patl2 -/- females exhibit lower in vivo MII rates (79.63%) than Patl2+/+ females (89.39%, P = 0.0123) but similar in vitro maturation rates (GV-MII = 48.74%) compared to Patl2+/+ females (52.85%, P = 0.5230). After PIEZO-ICSI with wild-type sperm, reduced AR (Patl2-/- = 31.71%, Patl2+/+ = 76.74%, P &lt; 0.0001) and BR (Patl2-/- = 7.69%, Patl2+/+ = 42.42%, P = 0.0237) were observed in knockout oocytes. However, Patl2-/- oocytes exhibited normal spindle rates (78.57%) as seen in Patl2+/+ oocytes (86.00%, P = 0.3491), as well as a similar capacity to sustain long-lasting calcium oscillations (A×F = 6.15 ± 4.80) compared to Patl2+/+ oocytes (A×F = 4.59 ± 2.96, P = 0.1453). Single-cell proteomics identified 4882 proteins and confirmed the absence of Patl2 in knockout oocytes, from analyzing 25 Patl2+/+ and 27 Patl2-/- MII oocytes. After filt","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"'The more, the better' a decade later. Still true?","authors":"Nikolaos P Polyzos, Valeria Donno","doi":"10.1093/humrep/deag036","DOIUrl":"https://doi.org/10.1093/humrep/deag036","url":null,"abstract":"","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":"41 5","pages":"647-649"},"PeriodicalIF":6.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissues: impact and legacy two decades latter.","authors":"Claus Yding Andersen, Marie-Madeleine Dolmans, Erik Ernst","doi":"10.1093/humrep/deag026","DOIUrl":"https://doi.org/10.1093/humrep/deag026","url":null,"abstract":"","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":"41 5","pages":"643-646"},"PeriodicalIF":6.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How big is the time window for cell-free fetal DNA testing after pregnancy loss and which factors are associated with a successful result?","authors":"Yasmin Isabella El Sammaa-Aru, Tanja Schlaikjær Hartwig, Maiken Hemme Bro-Jørgensen, Emma Juuel Münter, Lene Werge, Karina Banasik, Finn Stener Jørgensen, Louise Ambye, David Westergaard, Henriette Svarre Nielsen","doi":"10.1093/humrep/deag034","DOIUrl":"10.1093/humrep/deag034","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Study question: &lt;/strong&gt;How fast does cell-free fetal DNA (cffDNA) decline after early pregnancy loss and which factors affect the decline?&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Summary answer: &lt;/strong&gt;After pregnancy loss cffDNA declines gradually with detectable levels persisting up to 3 days post-tissue passage correlating with β-hCG decline.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;What is known already: &lt;/strong&gt;Postpartum clearance of cffDNA occurs within hours, but little is known about its decline following early pregnancy loss. Initial results from the Copenhagen Pregnancy Loss (COPL) study showed slower clearance in relation to pregnancy loss with detectable levels found up to 24 h after tissue passage.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Study design, size, duration: &lt;/strong&gt;This prospective cohort study included 1463 women from the COPL cohort, enrolled between 12 November 2020 and 19 December 2022. Participants were divided into three groups based on sampling time: the standard group (samples collected before tissue passage), the delayed sample group (samples collected after tissue passage at maximum 24 h), and the repeated sample group (samples collected at multiple time points after medical and surgical treatment).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Participants/materials, setting, methods: &lt;/strong&gt;Eligible women were 18 years old with a confirmed intrauterine pregnancy loss before 22 gestational weeks. Exclusion criteria included ectopic, molar, or unknown-location pregnancies and inability to consent. For the repeated sample group, additional exclusions were vaginal bleeding at diagnosis, anembryonic pregnancies, and opting for expectant management. Blood samples were analyzed for β-hCG and cffDNA, with fetal fraction measured using the sequencing-based fetal fraction (SeqFF) method. In the repeated sampling group, analyses were performed on Days 2 and 3 for surgically treated and Days 7 and 14 for medically treated.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main results and the role of chance: &lt;/strong&gt;After pregnancy tissue passage, both cffDNA and β-hCG levels declined consistently over time with a corresponding increase in no-call rates. The decline in SeqFF following pregnancy loss occurred more gradually than the immediate clearance previously reported after delivery, remaining measurable for up to 3 days after pregnancy loss, though 30% of samples became inconclusive at this timepoint. The fetal fraction of cffDNA was highest when tissue remained in utero and declined significantly beyond 12-h post-passage (median 4.7% &lt;6 h vs 2.8% &gt;12 h). The no call rate was 9.1% when the tissue was still in situ but increased to 27.1% in the 12- to 24-h post-passage group. Higher β-hCG levels correlated with increased odds of a conclusive cffDNA test (OR 1.30, 95% CI: 1.20-1.43, P &lt; 0.001). β-hCG is accounting for 20% of the variability in fetal fraction measurements. Variability in the decline of cffDNA between groups reflects the differences in the timing of sampling and treatment approaches.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Limitations, reasons for caution:","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":"712-721"},"PeriodicalIF":6.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147511816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concerns regarding the WHO guideline on infertility: implications for contemporary reproductive medicine.","authors":"Antonio La Marca,Maria Longo","doi":"10.1093/humrep/deag062","DOIUrl":"https://doi.org/10.1093/humrep/deag062","url":null,"abstract":"","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":"21 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147754549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply: Concerns regarding the WHO guideline on infertility: implications for contemporary reproductive medicine.","authors":"Gitau Mburu, Willem Ombelet, Tansu Kucuk, Robert W Rebar, Linda C Giudice, Jacky Boivin, Sandro C Esteves, Adam H Balen, Lan N Vuong, Nancy Santesso, Romina Brignardello-Petersen, Richard Kennedy, James Kiarie","doi":"10.1093/humrep/deag063","DOIUrl":"https://doi.org/10.1093/humrep/deag063","url":null,"abstract":"","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}